{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T13:10:09Z","timestamp":1716729009975},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,26]]},"DOI":"10.7759\/cureus.61105","type":"journal-article","created":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T12:32:00Z","timestamp":1716726720000},"source":"Crossref","is-referenced-by-count":0,"title":["The Serological Evidence of Positive Rheumatoid Factor in Morphea Patients and Its Relation to Disease Severity"],"prefix":"10.7759","author":[{"given":"Ahmed N","family":"Al-Nasrawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amenah S","family":"Abdulkareem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariem N","family":"Mohammed Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1401a23","article-title":"A comparison of clinical, demographic and treatment characteristics of pediatric-onset and adult-onset patients diagnosed with localized scleroderma","volume":"14","author":"Akba\u015f A","year":"2024","unstructured":"Akba\u015f A, K\u0131l\u0131n\u00e7 F, Hayran Y. A comparison of clinical, demographic and treatment characteristics of pediatric-onset and adult-onset patients diagnosed with localized scleroderma. Dermatol Pract Concept. 2024, 14:4-6. 10.5826\/dpc.1401a23","journal-title":"Dermatol Pract Concept"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1590\/abd1806-4841.20152890","article-title":"Localized scleroderma: clinical spectrum and therapeutic update","volume":"90","author":"Careta MF","year":"2015","unstructured":"Careta MF, Romiti R. Localized scleroderma: clinical spectrum and therapeutic update. An Bras Dermatol. 2015, 90:62-73. 10.1590\/abd1806-4841.20152890","journal-title":"An Bras Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-6222","article-title":"Morphea: progress to date and the road ahead","volume":"9","author":"Abbas L","year":"2021","unstructured":"Abbas L, Joseph A, Kunzler E, Jacobe HT. Morphea: progress to date and the road ahead. Ann Transl Med. 2021, 9:437. 10.21037\/atm-20-6222","journal-title":"Ann Transl Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-018-1897-1","article-title":"Association between quality of life and clinical characteristics in patients with morphea","volume":"27","author":"Bali G","year":"2018","unstructured":"Bali G, K\u00e1rp\u00e1ti S, S\u00e1rdy M, Brodszky V, Hidv\u00e9gi B, Rencz F. Association between quality of life and clinical characteristics in patients with morphea. Qual Life Res. 2018, 27:2525-32. 10.1007\/s11136-018-1897-1","journal-title":"Qual Life Res"},{"key":"ref5","article-title":"The role of infection in morphea disease","volume":"4","author":"Farhangdoost F","year":"2014","unstructured":"Farhangdoost F. The role of infection in morphea disease. Rev Clin Med. 2014, 4:32-4.","journal-title":"Rev Clin Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2831","article-title":"Granuloma annulare and morphea: correlation with Borrelia burgdorferi infections and Chlamydia-related bacteria","volume":"98","author":"Tolkki L","year":"2018","unstructured":"Tolkki L, Hokynar K, Meri S, Panelius J, Puolakkainen M, Ranki A. Granuloma annulare and morphea: correlation with Borrelia burgdorferi infections and Chlamydia-related bacteria. Acta Derm Venereol. 2018, 98:355-60. 10.2340\/00015555-2831","journal-title":"Acta Derm Venereol"},{"key":"ref7","article-title":"Morphea (localized Scleroderma) in a COVID-19 patient: a case report","volume":"4","author":"Capalbo A","year":"2021","unstructured":"Capalbo A, Gagliostro N, Balampanos G, Bushati V, Persechino F, Giordano D, Persechino S. Morphea (localized Scleroderma) in a COVID-19 patient: a case report. J Immunol Clin Microbiol. 2021, 4:4-6.","journal-title":"J Immunol Clin Microbiol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2022.2063841","article-title":"Immunologic underpinnings and treatment of morphea","volume":"18","author":"LaChance AH","year":"2022","unstructured":"LaChance AH, Goldman N, Kassamali B, Vleugels RA. Immunologic underpinnings and treatment of morphea. Expert Rev Clin Immunol. 2022, 18:461-83. 10.1080\/1744666X.2022.2063841","journal-title":"Expert Rev Clin Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.03.017","article-title":"Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations","volume":"85","author":"Chiu YE","year":"2021","unstructured":"Chiu YE, Shmuylovich L, Kiguradze T, et al.. Body site distribution of pediatric-onset morphea and association with extracutaneous manifestations. J Am Acad Dermatol. 2021, 85:38-45. 10.1016\/j.jaad.2021.03.017","journal-title":"J Am Acad Dermatol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.5301\/jsrd.5000215","article-title":"Localized scleroderma: a review","volume":"1","author":"Moinzadeh P","year":"2016","unstructured":"Moinzadeh P, Hunzelmann N, Kreuter A, Krieg T. Localized scleroderma: a review. J Scleroderma Relat Disord. 2016, 1:286-97. 10.5301\/jsrd.5000215","journal-title":"J Scleroderma Relat Disord"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/ced.13127","article-title":"Bullous morphoea: a retrospective study","volume":"42","author":"Venturi M","year":"2017","unstructured":"Venturi M, Pinna AL, Pilloni L, Atzori L, Ferreli C, Rongioletti F. Bullous morphoea: a retrospective study. Clin Exp Dermatol. 2017, 42:532-5. 10.1111\/ced.13127","journal-title":"Clin Exp Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2018.03.011","article-title":"Morphea in childhood: an update","volume":"109","author":"Aranegui B","year":"2018","unstructured":"Aranegui B, Jim\u00e9nez-Reyes J. Morphea in childhood: an update. Actas Dermosifiliogr. 2018, 109:312-22. 10.1016\/j.adengl.2018.03.011","journal-title":"Actas Dermosifiliogr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2018.04.005","article-title":"Morphea: current concepts","volume":"36","author":"Florez-Pollack S","year":"2018","unstructured":"Florez-Pollack S, Kunzler E, Jacobe HT. Morphea: current concepts. Clin Dermatol. 2018, 36:475-86. 10.1016\/j.clindermatol.2018.04.005","journal-title":"Clin Dermatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01487","article-title":"Autoantibodies in morphea: an update","volume":"10","author":"Khatri S","year":"2019","unstructured":"Khatri S, Torok KS, Mirizio E, Liu C, Astakhova K. Autoantibodies in morphea: an update. Front Immunol. 2019, 10:1487. 10.3389\/fimmu.2019.01487","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217624","article-title":"Immunoglobulin G structure and rheumatoid factor epitopes","volume":"14","author":"Maibom-Thomsen SL","year":"2019","unstructured":"Maibom-Thomsen SL, Trier NH, Holm BE, et al.. Immunoglobulin G structure and rheumatoid factor epitopes. PLoS One. 2019, 14:e0217624. 10.1371\/journal.pone.0217624","journal-title":"PLoS One"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.02.007","article-title":"The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population","volume":"69","author":"Kelsey CE","year":"2013","unstructured":"Kelsey CE, Torok KS. The Localized Scleroderma Cutaneous Assessment Tool: responsiveness to change in a pediatric clinical population. J Am Acad Dermatol. 2013, 69:214-20. 10.1016\/j.jaad.2013.02.007","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12829","article-title":"Autoantibodies and B Cells: the ABC of rheumatoid arthritis pathophysiology","volume":"294","author":"Volkov M","year":"2020","unstructured":"Volkov M, van Schie KA, van der Woude D. Autoantibodies and B Cells: the ABC of rheumatoid arthritis pathophysiology. Immunol Rev. 2020, 294:148-63. 10.1111\/imr.12829","journal-title":"Immunol Rev"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020686","article-title":"From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis","volume":"22","author":"Wu CY","year":"2021","unstructured":"Wu CY, Yang HY, Luo SF, Lai JH. From rheumatoid factor to anti-citrullinated protein antibodies and anti-carbamylated protein antibodies for diagnosis and prognosis prediction in patients with rheumatoid arthritis. Int J Mol Sci. 2021, 22:54-6. 10.3390\/ijms22020686","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.06.006","article-title":"On the origin of rheumatoid factors: insights from analyses of variable region sequences","volume":"48","author":"Falkenburg WJ","year":"2019","unstructured":"Falkenburg WJ, von Richthofen HJ, Rispens T. On the origin of rheumatoid factors: insights from analyses of variable region sequences. Semin Arthritis Rheum. 2019, 48:603-10. 10.1016\/j.semarthrit.2018.06.006","journal-title":"Semin Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2005.01776.x","article-title":"Rheumatoid factor isotypes in localized scleroderma","volume":"30","author":"Mimura Y","year":"2005","unstructured":"Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Rheumatoid factor isotypes in localized scleroderma. Clin Exp Dermatol. 2005, 30:405-8. 10.1111\/j.1365-2230.2005.01776.x","journal-title":"Clin Exp Dermatol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/s0190-9622(94)70217-9","article-title":"Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma","volume":"31","author":"Sato S","year":"1994","unstructured":"Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma. J Am Acad Dermatol. 1994, 31:567-71. 10.1016\/s0190-9622(94)70217-9","journal-title":"J Am Acad Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.08.052","article-title":"Skin mapping for the classification of generalized morphea","volume":"78","author":"Teske N","year":"2018","unstructured":"Teske N, Welser J, Jacobe H. Skin mapping for the classification of generalized morphea. J Am Acad Dermatol. 2018, 78:351-7. 10.1016\/j.jaad.2016.08.052","journal-title":"J Am Acad Dermatol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh487","article-title":"Localized scleroderma is an autoimmune disorder","volume":"44","author":"Takehara K","year":"2005","unstructured":"Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology (Oxford). 2005, 44:274-9. 10.1093\/rheumatology\/keh487","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00320-9","article-title":"Overview of juvenile localized scleroderma and its management","volume":"16","author":"Li SC","year":"2020","unstructured":"Li SC, Zheng RJ. Overview of juvenile localized scleroderma and its management. World J Pediatr. 2020, 16:5-18. 10.1007\/s12519-019-00320-9","journal-title":"World J Pediatr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.03.005","article-title":"Inflammatory arthritis in pediatric patients with morphea","volume":"79","author":"Kashem SW","year":"2018","unstructured":"Kashem SW, Correll CK, Vehe RK, Hobday PM, Binstadt BA, Maguiness SM. Inflammatory arthritis in pediatric patients with morphea. J Am Acad Dermatol. 2018, 79:47-51. 10.1016\/j.jaad.2018.03.005","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.1019","article-title":"Baseline description of the juvenile localized scleroderma subgroup from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry","volume":"1","author":"Wu EY","year":"2019","unstructured":"Wu EY, Li SC, Torok KS, Virkud YV, Fuhlbrigge RC, Rabinovich CE. Baseline description of the juvenile localized scleroderma subgroup from the Childhood Arthritis and Rheumatology Research Alliance Legacy Registry. ACR Open Rheumatol. 2019, 1:119-24. 10.1002\/acr2.1019","journal-title":"ACR Open Rheumatol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab238","article-title":"Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma","volume":"60","author":"Li SC","year":"2021","unstructured":"Li SC, Higgins GC, Chen M, et al.. Extracutaneous involvement is common and associated with prolonged disease activity and greater impact in juvenile localized scleroderma. Rheumatology (Oxford). 2021, 60:5724-33. 10.1093\/rheumatology\/keab238","journal-title":"Rheumatology (Oxford)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23101","article-title":"Predictors of longitudinal quality of life in juvenile localized scleroderma","volume":"69","author":"Ardalan K","year":"2017","unstructured":"Ardalan K, Zigler CK, Torok KS. Predictors of longitudinal quality of life in juvenile localized scleroderma. Arthritis Care Res (Hoboken). 2017, 69:1082-7. 10.1002\/acr.23101","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14161","article-title":"Diagnostic criteria, severity classification and guidelines of localized scleroderma","volume":"45","author":"Asano Y","year":"2018","unstructured":"Asano Y, Fujimoto M, Ishikawa O, et al.. Diagnostic criteria, severity classification and guidelines of localized scleroderma. J Dermatol. 2018, 45:755-80. 10.1111\/1346-8138.14161","journal-title":"J Dermatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei251","article-title":"Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study","volume":"45","author":"Zulian F","year":"2006","unstructured":"Zulian F, Athreya BH, Laxer R, et al.. Juvenile localized scleroderma: clinical and epidemiological features in 750 children. An international study. Rheumatology (Oxford). 2006, 45:614-20. 10.1093\/rheumatology\/kei251","journal-title":"Rheumatology (Oxford)"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/256509-the-serological-evidence-of-positive-rheumatoid-factor-in-morphea-patients-and-its-relation-to-disease-severity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T12:32:04Z","timestamp":1716726724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/256509-the-serological-evidence-of-positive-rheumatoid-factor-in-morphea-patients-and-its-relation-to-disease-severity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,26]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.61105","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,26]]}}}